Results 141 to 150 of about 5,026 (198)

Elucidating the enigmatic biology of arteriviruses through receptor discovery. [PDF]

J Virol
Bailey AL.
europepmc   +1 more source

What has changed in thyroid eye disease in the last five years (2020-2025). [PDF]

Eur Thyroid J
Salvi M.
europepmc   +1 more source

Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report. [PDF]

Cureus
Amano R.
europepmc   +1 more source

Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies. [PDF]

Oncologist
Inase A, Kimbara S, Imamura E, Phelps MA, Minami H.   +4 more
europepmc   +1 more source

Late-Onset Ocular Myasthenia Gravis-Like Symptoms During Erenumab Therapy for Chronic Migraine: A Case Report. [PDF]

Biologics
Qaqish A, Al Anber A, Abdelhafez G.
europepmc   +1 more source

Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study [PDF]

, 2015
Allen, G, Brown, SA, Cristiano, LM, Hanabusa, H, Jackson, S, Konkle, B, Li, X, Mahlangu, J, Pabinger-Fasching, I, Pasi, J, Perry, D, Pierce, GF, Rangarajan, S   +12 more
core  

Nipocalimab-aahu in generalised myasthenia gravis: A new Fc receptor-targeted option for antibody-positive patients. [PDF]

Ibrain
Hussain JM, Ashfaq A, Shahid A, Mudassir F.   +3 more
europepmc   +1 more source

Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives. [PDF]

Curr Opin Hematol
Pan L, Zhu J.
europepmc   +1 more source